加载中
NASDAQHealthcareMedical - Instruments & Supplies
最新数据
US$1.90
−US$0.16 · -7.77%
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
收盘时
US$1.90
−US$0.16 · -7.77%
盘中时间采用ET。市场数据可能有所延迟。
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
日内区间
当前US$1.90
52周区间
当前US$1.90
盘中时间采用ET。市场数据可能有所延迟。
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
日内区间
当前US$1.90
52周区间
当前US$1.90
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4.99万 USD | 4.83万 USD | 10.08万 USD | 5.66万 USD | 5.85万 USD |
| 销货成本 | 5.05万 USD | 5.13万 USD | 6.42万 USD | 3.66万 USD | 3.54万 USD |
| 毛利 | −645 USD | −3024 USD | 3.66万 USD | 2万 USD | 2.31万 USD |
| 研究与开发 | 22.69万 USD | 24.14万 USD | 16.77万 USD | 29.29万 USD | 27.98万 USD |
| 销售、一般及管理费用 | 439.46万 USD | 126.93万 USD | 83.34万 USD | 83.04万 USD | 24.82万 USD |
| 营业费用 | 456.7万 USD | 164.22万 USD | 110.49万 USD | 119.58万 USD | 57.58万 USD |
| 利息收入 | 2.66万 USD | — | — | — | — |
| 利息支出 | 1.47万 USD | 3.72万 USD | 5.66万 USD | 2017 USD | 2783 USD |
| 折旧和摊销 | 3.65万 USD | 4.22万 USD | 3.51万 USD | 2.91万 USD | 2.75万 USD |
| 营业利润 | −456.76万 USD | −164.53万 USD | −106.83万 USD | −117.58万 USD | −55.28万 USD |
| 净利润 | −467.34万 USD | −156.05万 USD | −111.96万 USD | −109.45万 USD | −51.97万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
